RANKL signaling in bone physiology and cancer
- 1 December 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 1 (4) , 317-322
Abstract
Increased osteoclast activity plays an operative role in the pathophysiology of skeletal complications of malignancy. This review focuses on the critical roles of a triad of molecules - receptor activator of nuclear factor kappa beta ligand and its two receptors, receptor activator of nuclear factor kappa beta and osteoprotegerin - in the regulation of osteoclastogenesis across a broad spectrum of cancer-induced bone diseases. While it is well established that osteoclastic bone resorption plays an operative role in the skeletal complications of 'osteolytic' bone metastasis, recent evidence has described osteoclasts in osteoblastic prostate cancer metastases and increases in serum markers of bone resorption in these patients. In addition to its essential role in osteoclastogenesis, receptor activator of nuclear factor kappa beta ligand has also been recently shown to increase migration and invasive properties of receptor activator of nuclear factor kappa beta-positive tumor cells, and potentially may play a direct role in the bone tropism of those tumors. The critical role of receptor activator of nuclear factor kappa beta ligand signaling in regulating osteoclast activity is described in detail in this review, as is its role in cancer-mediated bone destruction, and the potential of receptor activator of nuclear factor kappa beta ligand inhibition as a novel treatment in tumor-induced bone disease.Keywords
This publication has 59 references indexed in Scilit:
- Clinical Features of Metastatic Bone Disease and Risk of Skeletal MorbidityClinical Cancer Research, 2006
- MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKLCancer Cell, 2005
- Osteoclast differentiation and activationNature, 2003
- Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus*Endocrinology, 2001
- RANK is essential for osteoclast and lymph node developmentGenes & Development, 1999
- Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development1999
- OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature, 1999
- osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcificationGenes & Development, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997